PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

计划入组 30 人 · 首次发布于 2022 年 4 月 13 日

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

计划入组 65 人 · 首次发布于 2025 年 3 月 11 日

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

计划入组 56 人 · 首次发布于 2022 年 9 月 7 日

PD-L1 inhibitor(China Pharmaceutical University)

engineered-PD-1-based PD-L1 inhibitor (cancer)

Engineered-PD-1-based PD-L1 inhibitor(Ligand)

PD-RX Pharmaceuticals, Inc.

United States

3D MEDICINES

Hong Kong, China

Saul Centers Inc

United States

FDA Approves Roche's Tecentriq Hybreza, a Subcutaneous PD-L1 Inhibitor, for Multiple Cancers

Glenmark Initiates Global Phase 3 Trial for Subcutaneous PD-L1 Inhibitor Envafolimab in Stage III Lung Cancer

OmRx Oncology Launches Phase 2 Trial of Novel Oral PD-L1 Inhibitor for NSCLC, Targeting Global Access Disparities